KALY Confirms Hemp Derived CBD Sunscreen Product For $17 Billion Market And Marketing Overview Release Thursday May 2nd
30 Apr 2019
DALLAS, April 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company’s plans to publish an overview of the marketing plan for its hemp derived CBD sunscreen as indicated in last week’s release when the company announced it had developed a hemp derived CBD sunscreen formula for the
$17 billion global sun protection product market
. In informal, non-medical, trials of CBD infused lotion, users have reported the CBD formula has proven effective not only for protection from the sun, but relief and repair from sunburn. Coincidently, KALY partner, Puration, Inc. (USOTC: PURA) today released an announcement with spray tan company
Jan Tana
. Look for KALY’s sunscreen overview on Thursday, May 2, 2019 to include mention of PURA’s role.
To learn more about the company visit
https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.